Laxmi Dental
add_icon

Laxmi Dental

279.60
-1.05
(-0.37%)
Market Cap
₹1,536.74 Cr
PE Ratio
62.45
Volume
37,442.00
Day High - Low
₹284.35 - ₹279.00
52W High-Low
₹584.00 - ₹280.00
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
1,536.74 Cr
EPS
6.07
PB Ratio
7.07
Book Value
41.72
EBITDA
45.20
Dividend Yield
0.00 %
Industry
Healthcare
ROE Growth %
-
Debt to Equity
0.28
Analyst Rating and Forecast
- By Refinitiv from3 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %
Forecast For
Actual

Company News

View All News
Caret
positive
Laxmi Dental Limited achieved its strongest quarterly sales for the second consecutive time with revenue of Rs. 72 crores, representing 26.5% year-on-year growth, while maintaining healthy EBITDA margin of 15.3% and PAT margin of 11.8%. The company's dental lab business grew 29.9% excluding scanners, with domestic lab business up 23.2% to Rs. 22.5 crores and international lab business surging 39.2% to Rs. 18.5 crores, despite facing US tariff pressures that impacted margins by 90 basis points.
positive
Laxmi Dental expects revenue growth of 20-25% with PAT margins of 13-15% for FY26. The company reported PAT margins of 12.2% for H1 FY26 and anticipates H2 to perform better than H1. Management expressed confidence in maintaining strong growth and meeting full-year revenue guidance while preserving healthy margins, though subject to global uncertainties. The company has set a long-term EBITDA margin target of at least 20%.
neutral
Laxmi Dental Limited Files Corrigendum for Q2 FY2026 Financial ResultsNov 12, 2025
Laxmi Dental Limited filed a corrigendum for its unaudited standalone and consolidated financial results for the second quarter and half year ended September 30, 2025. The company inadvertently attached the standalone cash flow statement instead of the consolidated cash flow statement in its earlier submission. The corrigendum only corrects the cash flow statement attachment, with no changes to revenue, expenses, profit, or earnings per share figures. The consolidated results show revenue from operations of Rs. 728.05 million for Q2 and Rs. 1,394.07 million for H1, with profit after tax of Rs. 85.32 million and Rs. 168.62 million respectively. The standalone results reported revenue of Rs. 542.57 million for Q2 and Rs. 1,074.29 million for H1, with profit after tax of Rs. 65.70 million and Rs. 144.29 million respectively.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,934.00
#1 19,596.39
52.70
#1 1,759.00
22.62
#1 339
5.03
46.86
279.60
#2 1,536.74
#8 62.45
#5 242.40
#6 24.12
#4 25
#1 44.07
31.46
807.00
1,427.95
70.93
186.60
40.62
20
-
64.86
223.25
1,187.83
57.09
408.40
32.64
30
-67.96
31.02
240.97
1,071.13
#1 22.88
326.67
41.78
46
751.52
61.74
603.45
1,003.04
67.58
249.37
43.89
17
-14.81
51.96
336.95
641.55
41.70
136.30
#1 107.77
16
50.00
60.46
458.55
558.85
28.18
67.10
13.15
18
14.58
33.31
250.40
357.88
46.19
111.80
-1.43
8
0.00
31.91
274.00
288.07
40.26
89.85
-11.13
7
#1 892.83
49.66
Growth Rate
Revenue Growth
24.12 %
Net Income Growth
41.90 %
Cash Flow Change
437.79 %
ROE
-69.79 %
ROCE
-18.31 %
EBITDA Margin (Avg.)
42.80 %

Quarterly Financial Results

Quarterly Financials
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Revenue
48
55
66
57
61
63
66
73
Expenses
44
44
46
48
52
51
54
61
EBITDA
3
11
20
9
9
11
12
12
Operating Profit %
6 %
19 %
22 %
14 %
14 %
15 %
17 %
14 %
Depreciation
3
3
3
3
4
4
4
4
Interest
1
1
1
1
2
1
1
0
Profit Before Tax
-1
7
16
5
5
6
10
9
Tax
-3
-1
-1
-1
-0
2
1
1
Net Profit
2
8
17
6
5
4
8
9
EPS in ₹
76.30
1.46
3.24
2.12
0.88
0.79
1.53
1.59

Balance Sheet

Balance Sheet
2020
2021
2022
2023
2024
2025
Total Assets
106
106
103
97
135
285
Fixed Assets
39
43
40
40
46
51
Current Assets
53
50
60
53
64
187
Capital Work in Progress
0
7
0
0
0
0
Investments
0
0
0
0
6
10
Other Assets
66
57
63
56
83
224
Total Liabilities
106
106
103
97
135
285
Current Liabilities
46
46
59
57
67
57
Non Current Liabilities
11
15
20
20
23
19
Total Equity
49
44
23
20
45
209
Reserve & Surplus
37
33
9
6
31
198
Share Capital
12
12
0
0
0
11

Cash Flow

Cash Flow
2020
2021
2022
2023
2024
2025
Net Cash Flow
0
0
-3
4
-6
125
Investing Activities
-18
-9
3
-10
-11
-29
Operating Activities
12
10
-2
14
8
44
Financing Activities
6
-0
-4
-2
-3
111

Share Holding

% Holding
Sept 2024
Jan 2025
Mar 2025
Jun 2025
Sept 2025
Promoter
86.61 %
41.70 %
41.70 %
41.70 %
41.70 %
FIIs
0.00 %
29.49 %
34.24 %
33.59 %
32.39 %
DIIs
0.00 %
15.18 %
12.86 %
14.31 %
11.85 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
0.00 %
9.56 %
6.49 %
5.80 %
9.26 %
Others
13.39 %
4.07 %
4.70 %
4.60 %
4.80 %
No of Share Holders
13
13
29,482
27,957
37,909

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
13 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
13 Feb 2025 481.80 429.60
26 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
26 May 2025 394.40 393.80
12 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
12 Aug 2025 410.75 391.55
29 Sept 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
29 Sept 2025 333.60 316.90
11 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
11 Nov 2025 317.60 341.55

Announcements

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation8 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation8 days ago
Announcement under Regulation 30 (LODR)-Earnings Call Transcript8 days ago
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 12, 2025
Corrigendum To The Unaudited Standalone And Consolidated Financial Results For The Second Quarter And Half Year Ended On September 30 2025Nov 12, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 11, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationNov 11, 2025
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportNov 11, 2025
Results - Financial Results For Quarter And Half Year Ended September 30 2025Nov 11, 2025
Board Meeting Outcome for Outcome Of The Board Meeting Of Laxmi Dental Limited ("The Company") Held On November 11 2025 For The Approval Of The Financial Results Of The Company For The Quarter And Half Year Ended September 30 2025Nov 11, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 07, 2025
Board Meeting Intimation for Prior Intimation Of Board Meeting To Be Held On November 11 2025Nov 05, 2025
Announcement under Regulation 30 (LODR)-CessationOct 24, 2025
Announcement under Regulation 30 (LODR)-CessationOct 20, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 14, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportOct 01, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 29, 2025
Closure of Trading WindowSep 27, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionSep 19, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 19, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 08, 2025
Reg. 34 (1) Annual Report.Sep 06, 2025
Intimation Of 21St Annual General Meeting (AGM) Of The Company Scheduled To Be Held On Monday September 29 2025.Sep 06, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 05, 2025
Disclosure Under SEBI (Share Based Employee Benefits And Sweat Equity) Regulations 2021 - Modification Of ESOP Scheme.Aug 29, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementAug 29, 2025
Board Meeting Outcome for Outcome Of Board Of Directors Meeting Held Today I.E. Friday August 29 2025.Aug 29, 2025
Intimation Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015Aug 29, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 28, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 28, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 19, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 18, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 14, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 13, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 12, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationAug 12, 2025
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportAug 12, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementAug 12, 2025
Financial Results For The Quarter Ended 30Th June 2025.Aug 12, 2025
Board Meeting Outcome for Outcome Of Board Of Directors Meeting Held On Tuesday August 12 2025.Aug 12, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 07, 2025
Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter Ended June 30 2025.Aug 07, 2025
Board Comments On Fine Levied By The National Stock Exchange Of India Limited For Non-Compliance With Regulation 23(9) Of The SEBI (LODR) Regulations 2015.Jul 28, 2025
Announcement under Regulation 30 (LODR)-AcquisitionJul 28, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 08, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 07, 2025
Closure of Trading WindowJun 26, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 23, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 19, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
WhiteOak Capital Pharma and Healthcare Fund Direct - Growth
0.00%
-30174
-0.22%
-0.24%
Bandhan BSE Healthcare Index Fund Direct-Growth
0.04%
1
0.00%
0.04%
Mirae Asset Healthcare Fund Direct - Growth
0.45%
0
-0.03%
-0.04%
Quant Dynamic Asset Allocation Fund Direct - Growth
0.00%
0
0.00%
-1.14%
Bank of India Conservative Hybrid Fund Direct-Growth
0.19%
0
0.00%
-0.01%
Bank of India Small Cap Fund Direct-Growth
0.71%
0
-0.05%
-0.11%
DSP Healthcare Fund Direct - Growth
0.28%
0
-0.02%
-0.03%
Edelweiss Recently Listed IPO Fund Direct-Growth
0.00%
0
0.00%
0.00%
HDFC Non-Cyclical Consumer Fund Direct - Growth
0.32%
0
-0.02%
-0.04%
HDFC Pharma And Healthcare Fund Direct - Growth
1.03%
0
-0.08%
-0.12%
HSBC Consumption Fund Direct - Growth
0.45%
0
-0.04%
-0.08%
HSBC India Export Opportunities Fund Direct-Growth
0.86%
0
-0.01%
-0.05%
Quant Flexi Cap Fund Direct-Growth
0.00%
0
0.00%
-0.25%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct - Growth
0.78%
0
-0.05%
0.78%
Invesco India Smallcap Fund Direct - Growth
0.00%
0
0.00%
-0.18%
Kotak Consumption Fund Direct - Growth
0.48%
0
-0.07%
-0.12%
Kotak Healthcare Fund Direct - Growth
1.96%
0
-0.14%
0.43%
LIC MF Focused Fund Direct - Growth
1.58%
0
-0.13%
0.04%
Bandhan Small Cap Fund Direct-Growth
0.00%
0
0.00%
0.00%
Aditya Birla Sun Life Manufacturing Equity Fund Direct-Growth
0.23%
0
-0.02%
-0.04%
ICICI Prudential Exports and Services Fund Direct-Growth
0.62%
0
-0.04%
0.62%
Quant Healthcare Fund Direct - Growth
0.00%
0
0.00%
-2.55%
Quant Manufacturing Fund Direct - Growth
0.00%
0
0.00%
-0.93%
Quant Small Cap Fund Direct Plan-Growth
0.00%
0
0.00%
-0.02%
Tata ELSS Fund Direct-Growth
0.19%
0
-0.01%
-0.02%

Technical Indicators

RSI(14)
Neutral
31.46
ATR(14)
Volatile
11.91
STOCH(9,6)
Oversold
6.14
STOCH RSI(14)
Oversold
0.90
MACD(12,26)
Bearish
-3.06
ADX(14)
Weak Trend
14.98
UO(9)
Bullish
26.97
ROC(12)
Downtrend And Accelerating
-17.83
WillR(14)
Oversold
-99.00